Nanoparticle Engineering: The Small Ingredient Enhancing Formulations

27 September 2022 12:15 - 12:45

  • Nanoparticle engineering technologies such as CESS® have the power to enhance the pharmacokinetic properties of crystalline or amorphous APIs, maintaining tight control of particle size distribution and polymorphism.
  • This is supported by case study examples, including for budesonide, fenofibrate and atovaquone.
  • This presentation will showcase the data demonstrating the enormous power of nanoparticle engineering, and further discuss how nanoformed particles can even enable oral formulations with delayed release.
  • The wider implications for drug development will also be explored.
This presentation will dive into the power of advanced nanoparticle engineering technology, and in particular Controlled Expansion of Supercritical Solutions (CESS®), for controlling particle size distribution, crystalline vs. amorphous form, polymorphism, and for enhancing pharmacokinetic properties. It will feature case study examples of controlled nanoparticle formation for budesonide, fenofibrate and atovaquone. The talk will showcase in-vivo and in-vitro data demonstrating how nanoparticle engineering can be applied to enhance dissolution and even enable oral formulations with delayed release. The broader implications for drug development will also be discussed.

Dr Christopher Worrall, VP US Business Development, Nanoform

Back to programme